As­traZeneca hands off epilep­sy pro­grams to Ovid; Amy­lyx scores pri­or­i­ty re­view for ALS drug 

Still re­cov­er­ing from a set­back in its lead pro­gram, Ovid Ther­a­peu­tics has turned to As­traZeneca for a suite of ex­per­i­men­tal epilep­sy drugs.

Ovid is pay­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER